ALEC Straddle Strategy

ALEC (Alector, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALEC (Alector, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $238.7M, a beta of 0.65 versus the broader market, a 52-week range of 1.01-3.4, average daily share volume of 721K, a public-listing history dating back to 2019, approximately 175 full-time employees. These structural characteristics shape how ALEC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.65 indicates ALEC has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on ALEC?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current ALEC snapshot

As of May 15, 2026, spot at $2.21, ATM IV 125.60%, IV rank 24.74%, expected move 36.01%. The straddle on ALEC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on ALEC specifically: ALEC IV at 125.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a ALEC straddle, with a market-implied 1-standard-deviation move of approximately 36.01% (roughly $0.80 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALEC expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALEC should anchor to the underlying notional of $2.21 per share and to the trader's directional view on ALEC stock.

ALEC straddle setup

The ALEC straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALEC near $2.21, the first option leg uses a $2.21 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALEC chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALEC shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$2.21N/A
Buy 1Put$2.21N/A

ALEC straddle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

ALEC straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on ALEC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on ALEC

Straddles on ALEC are pure-volatility plays that profit from large moves in either direction; traders typically buy ALEC straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

ALEC thesis for this straddle

The market-implied 1-standard-deviation range for ALEC extends from approximately $1.41 on the downside to $3.01 on the upside. A ALEC long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ALEC IV rank near 24.74% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ALEC at 125.60%. As a Healthcare name, ALEC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALEC-specific events.

ALEC straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALEC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALEC alongside the broader basket even when ALEC-specific fundamentals are unchanged. Always rebuild the position from current ALEC chain quotes before placing a trade.

Frequently asked questions

What is a straddle on ALEC?
A straddle on ALEC is the straddle strategy applied to ALEC (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ALEC stock trading near $2.21, the strikes shown on this page are snapped to the nearest listed ALEC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ALEC straddle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ALEC straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 125.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ALEC straddle?
The breakeven for the ALEC straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALEC market-implied 1-standard-deviation expected move is approximately 36.01%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on ALEC?
Straddles on ALEC are pure-volatility plays that profit from large moves in either direction; traders typically buy ALEC straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current ALEC implied volatility affect this straddle?
ALEC ATM IV is at 125.60% with IV rank near 24.74%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ALEC analysis